Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 30, 2026Biochemical and Biophysical Research Communications

Non-coding RNAs show promise as non-invasive biomarkers and therapeutic targets for diabetic cardiomyopathy.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Evidence on the mechanistic, diagnostic, prognostic, and therapeutic roles of ncRNAs in DCM remained scattered across the literature without a single integrated synthesis.

Design

Review

Key result

Non-coding RNAs show promise as novel non-invasive biomarkers and therapeutic targets for the effective management of diabetic cardiomyopathy, pending further large-scale clinical validation.

Authors

FUFarhan UllahPrince Mohammad bin Fahd UniversityHAHamad AliJamia Hamdard

Discussion

Loading...

Member takes

Overview

Non-coding RNAs merit prioritized translational research in diabetic cardiomyopathy; leaves open their adoption as biomarkers or targets.

Key Points

  • To consolidate mechanistic knowledge on non-coding RNAs in diabetic cardiomyopathy and evaluate their potential as diagnostic, prognostic, and therapeutic tools.
  • Literature synthesis integrating mechanistic, diagnostic, prognostic, and therapeutic evidence on non-coding RNAs (miRNAs, lncRNAs, and circRNAs) in diabetic cardiomyopathy.
  • Non-coding RNAs regulate major pathological pathways in diabetic cardiomyopathy, including cardiac hypertrophy, apoptosis, oxidative stress, inflammation, and mitochondrial dysfunction.
  • Specific stable and tissue-specific non-coding RNAs show utility as diagnostic and prognostic non-invasive biomarkers.
  • Targeted modulation of dysregulated non-coding RNAs improves cardiac function in preclinical experimental models.

Structured PICO

P
Population
Diabetic cardiomyopathy (DCM)
E
Exposure
Modulation of non-coding RNAs (miRNAs, lncRNAs, circRNAs)
O
Outcome
Mechanistic, diagnostic, prognostic, and therapeutic roles of ncRNAs in DCM

This review highlights the emerging role of non-coding RNAs as potential diagnostic biomarkers and therapeutic targets in diabetic cardiomyopathy.

Limitations

  • Further large-scale validation is required before clinical translation.
  • Further large-scale validation is required before clinical translation

Cite This Study

Ullah et al. (2026) conducted a review in Diabetic cardiomyopathy (DCM). Non-coding RNAs (ncRNAs) was evaluated. Non-coding RNAs show promise as novel non-invasive biomarkers and therapeutic targets for the effective management of diabetic cardiomyopathy, pending further large-scale clinical validation.

synapsesocial.com/papers/6a93e9e03affd7f5e23e6b50https://doi.org/10.1016/j.bbrc.2026.154514
View Full Paper
Ask AI
Bookmark
Share